Treatments and outcomes of patients with antiphospholipid antibody-related chorea
| PUMCH (n=13) | Literature (n=167) | Overall (n=180) | |
| Treatments | |||
| Symptomatic treatment | 9/12 (75.0) | 80/153 (46.1) | 89/165 (53.9) |
| Haloperidol | 2/9 (22.2) | 31/80 (38.8) | 33/89 (37.1) |
| Tetrabenazine | 0/9 (0) | 11/80 (13.8) | 11/89 (12.4) |
| Clonazepam | 7/9 (77.8) | 6/80 (7.5) | 13/89 (14.6) |
| AC | 5/12 (41.7) | 42/153 (27.5) | 47/165 (28.5) |
| AP | 9/12 (75.0) | 57/153 (37.3) | 66/165 (40.0) |
| Hydroxychloroquine | 12/12 (100.0) | 12/153 (7.8) | 24/165 (14.5) |
| GC | 11/12 (91.7) | 90/153 (58.8) | 101/165 (61.2) |
| Prednisone mono | 4/11 (36.4) | 46/90 (51.1) | 50/101 (49.5) |
| Pulses of methylprednisolone | 7/11 (63.6) | 21/90 (23.3) | 28/101 (27.7) |
| IST | 11/12 (83.3) | 21/153 (13.7) | 32/165 (19.4) |
| Cyclophosphamide | 4/11 (36.4) | 9/21 (42.9) | 13/32 (40.6) |
| Mycophenolate mofetil | 7/11 (63.6) | 5/21 (23.8) | 12/32 (37.5) |
| Azathioprine | 2/11 (18.2) | 9/21 (42.9) | 11/32 (34.4) |
| Tacrolimus | 1/11 (9.1) | 1/21 (4.8) | 2/32 (6.3) |
| Intravenous immunoglobulin | 2/12 (16.7) | 11/153 (7.2) | 13/165 (7.9) |
| Plasma exchange | 0/12 (0) | 2/153 (1.3) | 2/165 (1.2) |
| Rituximab | 1/12 (8.3) | 3/153 (2.0) | 4/165 (2.4) |
| Belimumab | 1/12 (8.3) | 1/153 (0.7) | 2/165 (1.2) |
| Outcomes | |||
| Complete resolution | 7/12 (58.3) | 94/123 (76.4) | 101/135 (74.8) |
| Improved | 5/12 (41.7) | 23/123 (18.7) | 28/135 (20.7) |
| Worsened | 0/12 (0) | 2/123 (1.6) | 2/135 (1.5) |
| Unchanged | 0/12 (0) | 4/123 (3.3) | 4/135 (3.0) |
| Per cent of complete resolution using AC/AP without GC/IST | 0/0 (0) | 18/37 (48.6) | 18/37 (48.6) |
| Per cent of complete resolution using AC/AP with GC/IST | 7/12 (58.3) | 33/53 (62.3) | 40/65 (61.5) |
Results are shown as n/N (%), excluding missing/unknown unless otherwise specified.
AC, anticoagulation; AP, antiplatelet; GC, glucocorticoids; IST, immunosuppressive therapies; PUMCH, Peking Union Medical College Hospital.